10 studies found for:    J591
Show Display Options
Rank Status Study
1 Unknown  Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel;   Drug: Prednisone;   Drug: 177Lu-J591
2 Unknown  Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
Condition: Prostate Cancer
Intervention: Drug: 117Lu-J591
3 Recruiting 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: 177Lu-J591;   Drug: Ketoconazole;   Drug: Hydrocortisone;   Drug: 111In-J591
4 Completed Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
5 Unknown  177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
6 Completed Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
Condition: Prostatic Neoplasms
Interventions: Drug: Monoclonal Antibody J591;   Drug: Recombinant Interleukin-2
7 Completed Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate
Condition: Prostate Cancer
Intervention: Radiation: lutetium Lu 177 monoclonal antibody J591
8 Completed Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: monoclonal antibody huJ591
9 Completed Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: monoclonal antibody muJ591;   Radiation: iodine I 131 monoclonal antibody muJ591
10 Active, not recruiting Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 89Zr-DFO-huJ591

Indicates status has not been verified in more than two years